Background and Rationale Essential tremor (ET) affects over 6 million Americans and approximately 5% of adults over age 60. Patients with ET have a 10-20 times higher risk of developing Parkinson's disease (PD) compared to age-matched populations, with approximately 1% converting to PD annually. Post-mortem studies reveal Lewy body pathology in some ET patients, suggesting a subset may have prodromal PD. Current diagnostic tools (DaTscan, SYNTap) are either insufficiently sensitive for early disease, too expensive, or too invasive for routine screening. The Syn-One Test offers a minimally invasive approach to detect phosphorylated α-synuclein (P-SYN) pathology in skin biopsies. Primary Objectives 1. Identify which ET patients have P-SYN pathology indicative of prodromal PD 2. Predict which patients are most likely to phenoconvert to PD
Study Type
OBSERVATIONAL
Enrollment
300
CND Clinical Research Center
Scottsdale, Arizona, United States
RECRUITINGQuantity of P-SYN in skin
Quantity of P-SYN in biopsies as a biomarker for disease progression
Time frame: From enrollment to completion of study participation from Baseline to Month 12 and then to Month 24
Rate of Phenoconversion
Rate of phenoconversion from Essential Tremor to Parkinson's Disease over 24 months
Time frame: From enrollment to completion of study participation from Baseline to Month 12 and then to Month 24
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.